These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33558338)

  • 1. "3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy.
    An O; Song Y; Ke X; So JB; Sundar R; Yang H; Rha SY; Lee MH; Tay ST; Ong X; Tan ALK; Ng MCH; Tantoso E; Chen L; Tan P; Yong WP;
    Cancer Res; 2021 May; 81(10):2788-2798. PubMed ID: 33558338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study.
    Zhu L; Wang H; Jiang C; Li W; Zhai S; Cai X; Wang X; Liao L; Tao F; Jin D; Chen G; Xia Y; Mao JH; Li B; Wang P; Hang B
    EBioMedicine; 2020 Nov; 61():103023. PubMed ID: 33069062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.
    Li X; Cai H; Zheng W; Tong M; Li H; Ao L; Li J; Hong G; Li M; Guan Q; Yang S; Yang D; Lin X; Guo Z
    Oncotarget; 2016 Feb; 7(8):8743-55. PubMed ID: 26840027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
    Smyth EC; Nyamundanda G; Cunningham D; Fontana E; Ragulan C; Tan IB; Lin SJ; Wotherspoon A; Nankivell M; Fassan M; Lampis A; Hahne JC; Davies AR; Lagergren J; Gossage JA; Maisey N; Green M; Zylstra JL; Allum WH; Langley RE; Tan P; Valeri N; Sadanandam A
    Ann Oncol; 2018 Dec; 29(12):2356-2362. PubMed ID: 30481267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients.
    Zhu C; Yang Q; Xu J; Zhao W; Zhang Z; Xu D; Zhang Y; Zhao E; Zhao G
    J Transl Med; 2019 Apr; 17(1):109. PubMed ID: 30944005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
    Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
    Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer.
    Cheong JH; Wang SC; Park S; Porembka MR; Christie AL; Kim H; Kim HS; Zhu H; Hyung WJ; Noh SH; Hu B; Hong C; Karalis JD; Kim IH; Lee SH; Hwang TH
    Nat Commun; 2022 Feb; 13(1):774. PubMed ID: 35140202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
    Kim HK; Choi IJ; Kim CG; Kim HS; Oshima A; Michalowski A; Green JE
    PLoS One; 2011 Feb; 6(2):e16694. PubMed ID: 21364753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
    Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
    Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of microRNA expression profiles reveals a 5‑microRNA prognostic signature for predicting overall survival time in patients with gastric adenocarcinoma.
    Zhao R; Zhao L; Xu X; Xu H
    Oncol Rep; 2019 May; 41(5):2775-2789. PubMed ID: 30864737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
    Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
    Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
    Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
    J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide analysis to identify a novel distant metastasis-related gene signature predicting survival in patients with gastric cancer.
    Hu BL; Xie MZ; Li KZ; Li JL; Gui YC; Xu JW
    Biomed Pharmacother; 2019 Sep; 117():109159. PubMed ID: 31247467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
    Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
    Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
    Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
    Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
    Yong WP; Rha SY; Tan IB; Choo SP; Syn NL; Koh V; Tan SH; Asuncion BR; Sundar R; So JB; Shabbir A; Tan CS; Kim HS; Jung M; Chung HC; Ng MCH; Tai DW; Lee MH; Wu J; Yeoh KG; Tan P;
    Clin Cancer Res; 2018 Nov; 24(21):5272-5281. PubMed ID: 30045931
    [No Abstract]   [Full Text] [Related]  

  • 19. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
    Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
    Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA methylation signature to improve survival prediction of gastric cancer.
    Peng Y; Wu Q; Wang L; Wang H; Yin F
    Clin Epigenetics; 2020 Jan; 12(1):15. PubMed ID: 31959204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.